MedTrace Logo

Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects

NCT02211170 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-08-07

No results posted yet for this study

Summary

Study to determine the effect of a single dose BIRB 796 BS on systemic inflammatory responses induced by endotoxin in healthy humans

Conditions

  • Healthy

Interventions

DRUG

BIBR 796 BS, low dose

DRUG

BIBR 796 BS, high dose

DRUG

Placebo

DRUG

Lipopolysaccharide

Lipopolysaccharide (LPS) for endotoxin challenge

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-02-29
Primary Completion
2000-04-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02211170 on ClinicalTrials.gov